Archives

Perfusfind S.L.

Abstract Objectives:  Despite increasing use and promising outcomes, venovenous extracorporeal membrane oxygenation (V-V ECMO) introduces the risk of a number of complications across the spectrum of ECMO care. This narrative review describes..

Perfusfind S.L.

Abstract We aimed to assess the efficacy and safety of extracorporeal membrane oxygenation (ECMO) in patients under mechanical ventilation with COVID-19 and severe acute respiratory distress syndrome (ARDS). A systematic..

Perfusfind S.L.

Abstract Objective To evaluate a restrictive transfusion policy of red blood cells (RBC) and platelets in pediatric patients submitted to extracorporeal membrane oxygenation (ECMO). Methods Retrospective descriptive study of pediatric..

Perfusfind S.L.

Abstract Aims Unfractionated heparin (UFH) has been the primary anticoagulant of choice on extracorporeal membrane oxygenation (ECMO). However, it is debatable whether bivalirudin (BIV), a direct thrombin inhibitor, may be..

Perfusfind S.L.

Abstract During the coronavirus disease (COVID-19) pandemic, the number of patients eligible to receive extracorporeal membrane oxygenation (ECMO) has exceeded the availability of this resource-intensive therapy (). To maximize benefit,..

Perfusfind S.L.

Abstract The ProtekDuo, single site dual lumen cannula can be used in a multitude of configurations. In the medical literature, the ProtekDuo is described as right ventricular assist device (RVAD),..

Perfusfind S.L.

Abstract Fungal infections are common and frequently associated with clinical failure in patients receiving extracorporeal membrane oxygenation (ECMO). Antifungal drugs have physicochemical characteristics associated with a higher likelihood of sequestration..

Perfusfind S.L.

Abstract We aimed to investigate the prevalence and associated factors of newly diagnosed end-stage renal disease (ESRD) requiring renal-replacement therapy (RRT) among survivors of extracorporeal membrane oxygenation (ECMO) and determine..

Perfusfind S.L.

Abstract The coronavirus disease 2019 (COVID-19) pandemic has been associated with the significant use of venovenous extracorporeal membrane oxygenation (VVECMO) globally. Identifying strategies to optimize care is essential to improving..

Perfusfind S.L.

Abstract An extracorporeal membrane oxygenation (ECMO) program is an important component in the management of patients with COVID-19, but it is imperative to implement a system that is well-supported by..

Perfusfind S.L.

Abstract OBJECTIVES Our goal was to compare the haemodynamic effects of different mechanical left ventricular (LV) unloading strategies and clinical outcomes in patients with refractory cardiogenic shock supported with venoarterial..

Perfusfind S.L.

Abstract Veno-venous Extracorporeal Membrane Oxygenation (ECMO) is used in the most severe cases of respiratory failure and further exacerbates the patients’ inflammatory status. Antithrombin is supplemented during ECMO for its..

Perfusfind S.L.

Abstract Objectives A paucity of data supports the use of transesophageal echocardiography (TEE) for bedside extracorporeal membrane oxygenation (ECMO) cannulation. Concerns have been raised about performing TEEs in patients with..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) offers hope for patients with acute respiratory distress syndrome when other treatment methods fail. However, ECMO requires continuous hourly management leading to extremely high operating costs...

Perfusfind S.L.

Abstract The increasing prevalence of chronic lung disease worldwide, combined with the emergence of multiple pandemics arising from respiratory viruses over the past century, highlights the need for safer and..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (VA-ECMO) provides cardiovascular and respiratory support for patients in cardiogenic shock; yet, complications are a frequent source of morbidity and mortality. Limb ischemia can be..

Perfusfind S.L.

Abstract Introduction: Clot formation, infection, and biofouling are unfortunate but frequent complications associated with the use of blood-contacting medical devices. The challenge of blood-foreign surface interactions is exacerbated during medical..

Perfusfind S.L.

Abstract Background: The mortality rate for a patient with a refractory cardiogenic shock on venoarterial (VA) extracorporealmembrane oxygenation (ECMO) remains high, and hyperoxia might worsen this prognosis. The objective of..

Perfusfind S.L.

Abstract OBJECTIVE:  Patient selection for pediatric extracorporeal membrane oxygenation (ECMO) support has broadened over the years to include children with pre-existing neurologic morbidities. We aimed to determine the prevalence and..

Perfusfind S.L.

Abstract Venovenous extracorporeal membrane oxygenation (VV ECMO) has been used to treat severe coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome; however, patient selection criteria have evolved throughout the pandemic...

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) is a lifesaving support for respiratory and cardiovascular failure. However, ECMO induces a systemic inflammatory response syndrome that can lead to various complications, including endothelial..

Perfusfind S.L.

Abstract Exchanging circuits in patients undergoing extracorporeal life support (ECLS) for component failure can be a life-threatening endeavor if the patient has no native organ function and is fully dependent..

Perfusfind S.L.

Abstract Extracorporeal hemoadsorption with the CytoSorb adsorber is increasingly being used during the past years. The use in combination with extracorporeal membrane oxygenation (ECMO) is feasible, but frequency of its use and..

Perfusfind S.L.

Abstract Intensive care unit (ICU) patients with end‑organ failure will require specialised machines or extracorporeal therapiesto support the failing organs that would otherwise lead to death. ICU patients with severe..

Perfusfind S.L.

Abstract The use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) for the treatment of refractory cardiogenic shock has increased signifcantly. Nevertheless, early weaning may be advisable to reduce the potential..

Perfusfind S.L.

Abstract Objectives Intra-device thrombosis remains one of the most common complications during extracorporeal membrane oxygenation (ECMO). Despite anticoagulation, approximately 35% of patients develop thrombi in the membrane oxygenator, pump heads,..

Perfusfind S.L.

Abstract Selecting patients most likely to benefit from venoarterial extracorporeal membrane oxygenation (V-A ECMO) to treat refractory drug-induced cardiovascular shock remains a difficult challenge for physicians. This study reported short-term..

Perfusfind S.L.

Abstract Cardiogenic shock and cardiac arrest contribute pre-dominantly to mortality in acute cardiovascular care. Here, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has emerged as an established therapeutic option for patients suffering..

Perfusfind S.L.

Abstract The need for biventricular support poses significant challenges for patients who require a mechanical bridge to transplantation. Recent improvements in ventricular assist device (VAD) technology has made possible the..

Perfusfind S.L.

Abstract A study published in March 2022 evaluated complications and in-hospital mortality in patients treated with Venovenous (VV) ECMO based on cannula locations and transport mode. The manuscript, written by..